Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggressive NHL and ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJennifer CrodenCDCarina Debes-MarunISIrwindeep Sandhu

Discussion

Loading...

Member takes

Overview

Analysis demonstrates improved collection efficiency in CAR T-cell treatment for non-Hodgkin lymphoma and leukemia patients.

Key Points

  • Achieving treatment targets in CAR T-cell therapy significantly improves with accurate apheresis timing.
  • Clinical trial data reveals enhanced collection efficiency in patients with non-Hodgkin lymphoma and leukemia.
  • Apheresis procedures were well-tolerated with no major adverse events, ensuring safety among patients.
  • Real-time adjustments during procedures are crucial for maintaining effective T-cell collection outcomes.

Cite This Study

Croden et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db3ehttps://doi.org/10.1182/blood-2025-5962
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlation of T cell fitness of apheresis products with response to CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma: A prospective observational study at a single center2025
  2. 2Platelet decrease and efficacy of platelet-rich plasma return for CAR-T lymphocyte apheresis in low-weight patients2025
  3. 3Lymphocyte kinetics as a predictor of clinical outcomes following CAR-T therapy for non-Hodgkin lymphoma2025
  4. 4Predictive biomarkers validation of CD3+ cell apheresis yield in CAR-T manufacturing for diffuse large B-cell lymphoma: a machine learning approach2025 · 2 citations
  5. 5Peripheral blast count at apheresis as a risk factor for survival following tisagenlecleucel in children and young adults2025